{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:52:54Z","timestamp":1777351974615,"version":"3.51.4"},"reference-count":30,"publisher":"American Psychiatric Association Publishing","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2002,5,1]]},"DOI":"10.1176\/appi.ajp.159.5.755","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T18:21:35Z","timestamp":1034360495000},"page":"755-760","source":"Crossref","is-referenced-by-count":35,"title":["Fluorine Magnetic Resonance Spectroscopy Measurement of Brain Fluvoxamine and Fluoxetine in Pediatric Patients Treated for Pervasive Developmental Disorders"],"prefix":"10.1176","volume":"159","author":[{"given":"Wayne L.","family":"Strauss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan S.","family":"Unis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldine","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen R.","family":"Dager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"230","reference":[{"key":"R1595BABBAJEE","doi-asserted-by":"crossref","unstructured":"Schain RJ, Freedman DX: Studies on 5-hydoxyindole metabolism in autism and other mentally retarded children. J Pediatr 1961; 59:315-320","DOI":"10.1016\/S0022-3476(61)80261-8"},{"key":"atypb1","doi-asserted-by":"crossref","unstructured":"Todd RD, Ciaranello RD: Demonstration of inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child. Proc Natl Acad Sci USA 1985; 82:612-616","DOI":"10.1073\/pnas.82.2.612"},{"key":"atypb2","doi-asserted-by":"crossref","unstructured":"McBride PA, Anderson GM, Hertzig ME, Sweeney JA, Kream J, Cohen DJ, Mann J: Serotonergic responsivity in male young adults with autistic disorder. Arch Gen Psychiatry 1989; 46:213-221","DOI":"10.1001\/archpsyc.1989.01810030019003"},{"key":"atypb3","doi-asserted-by":"crossref","unstructured":"Chugani DC, Muzik O, Rothermel R, Behen M, Chakraborty P, Mangner T, Dasilva E, Chugani HT: Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann Neurol 1997; 42:666-669","DOI":"10.1002\/ana.410420420"},{"key":"R1595BABICGII","doi-asserted-by":"crossref","unstructured":"Cook EH, Courchesne R, Lord C, Cox NJ, Yan S, Lincoln A, Hass R, Courchesne E, Leventhal BL: Evidence of linkage between the serotonin transporter and autistic disorder. Mol Psychiatry 1997; 2:247-250","DOI":"10.1038\/sj.mp.4000266"},{"key":"R1595BABDHCHG","doi-asserted-by":"crossref","unstructured":"McDougle CJ, Price LH, Volkmar FR, Goodman WK, Ward-O\u2019Brien D, Nielsen J, Bregman J, Cohen DJ: Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry 1992; 31:746-750","DOI":"10.1097\/00004583-199207000-00025"},{"key":"R1595BABFHJDF","doi-asserted-by":"crossref","unstructured":"McDougle CH, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LY: A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53:1001-1008","DOI":"10.1001\/archpsyc.1996.01830110037005"},{"key":"atypb4","doi-asserted-by":"crossref","unstructured":"Mehlinger R, Scheftner WA, Poznanski E: Fluoxetine and autism (letter). J Am Acad Child Adolesc Psychiatry 1990; 29:985","DOI":"10.1097\/00004583-199011000-00032"},{"key":"atypb5","doi-asserted-by":"crossref","unstructured":"Fatemi SH, Realmuto GM, Khan L, Thuras P: Fluoxetine in the treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 1998; 28:303-307","DOI":"10.1023\/A:1026008602540"},{"key":"atypb6","doi-asserted-by":"crossref","unstructured":"Koshes RJ: Use of fluoxetine for obsessive-compulsive behavior in adults with autism (letter). Am J Psychiatry 1997; 154:578","DOI":"10.1176\/ajp.154.4.578a"},{"key":"atypb7","doi-asserted-by":"crossref","unstructured":"Gordon CT, Rapoport JL, Hamburger SD, State RC, Mannheim CB: Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Am J Psychiatry 1992; 149:363-366","DOI":"10.1176\/ajp.149.3.363"},{"key":"atypb8","doi-asserted-by":"crossref","unstructured":"Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL: A double-blind comparison of clomipramine, desipramine and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50:441-447","DOI":"10.1001\/archpsyc.1993.01820180039004"},{"key":"atypb9","doi-asserted-by":"crossref","unstructured":"Ghaziuddin M, Tsai L, Ghaziuddin N: Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry 1991; 30:508-509","DOI":"10.1097\/00004583-199105000-00029"},{"key":"atypb10","doi-asserted-by":"crossref","unstructured":"Garber HJ, McGonigle JJ, Slomka GT, Monteverde E: Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities. J Am Acad Child Adolesc Psychiatry 1992; 31:1157-1160","DOI":"10.1097\/00004583-199211000-00027"},{"key":"atypb11","doi-asserted-by":"crossref","unstructured":"Cook EH, Rowlett R, Jaselskis C, Leventhal BL: Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992; 31:739-745","DOI":"10.1097\/00004583-199207000-00024"},{"key":"R1595BABDBBHI","doi-asserted-by":"crossref","unstructured":"Todd RD: Fluoxetine in autism (letter). Am J Psychiatry 1991; 148:1089","DOI":"10.1176\/ajp.148.8.1089b"},{"key":"R1595BABEAAAB","unstructured":"Devane CL, Sallee FR: Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. J Clin Psychiatry 1996; 57:55-66"},{"key":"R1595BABGBEFA","doi-asserted-by":"crossref","unstructured":"Zito JM, Safer DJ, dis Reis S, Gardner JF, Boles M, Lynch F: Trends in the prescribing of psychotropic medications in preschoolers. JAMA 2000; 283:1025-1030","DOI":"10.1001\/jama.283.8.1025"},{"key":"R1595BABBHDDI","unstructured":"Dager SR, Steen RG: Applications of magnetic resonance spectroscopy to the investigation of neuropsychiatric disorders. Neuropsychopharmacology 1992; 6:249-266"},{"key":"R1595BABHHFHD","doi-asserted-by":"crossref","unstructured":"Strauss WL, Layton ME, Hayes CE, Dager SR: 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Am J Psychiatry 1997; 154:516-522","DOI":"10.1176\/ajp.154.4.516"},{"key":"R1595BABEJAJJ","doi-asserted-by":"crossref","unstructured":"Strauss WL, Layton ME, Dager SR: Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. Am J Psychiatry 1998; 155:380-384","DOI":"10.1176\/ajp.155.3.380"},{"key":"R1595BABFDACA","doi-asserted-by":"crossref","unstructured":"Strauss WL, Layton ME, Dager SR: Characterization of human brain pharmacokinetics using a two-compartment model. Biol Psychiatry 1999; 45:1384-1388","DOI":"10.1016\/S0006-3223(98)00324-2"},{"key":"R1595BABDDCDH","doi-asserted-by":"crossref","unstructured":"Strauss WL, Dager SR: Magnetization transfer of fluoxetine in human brain using fluorine magnetic resonance spectroscopy. Biol Psychiatry 2001; 49:798-802","DOI":"10.1016\/S0006-3223(00)01121-5"},{"key":"R1595BABBIIEC","doi-asserted-by":"crossref","unstructured":"Giedd JN, Snell JW, Lange N, Rajapakse JC, Casey BJ, Kozuch PL, Vaituzis AC, Vauss YC, Hamburger SD, Kaysen D, Rapoport JL: Quantitative magnetic resonance imaging of human brain development: ages 4 to 18. Cereb Cortex 1996; 6:551-560","DOI":"10.1093\/cercor\/6.4.551"},{"key":"R1595BABGIACC","doi-asserted-by":"crossref","unstructured":"Caviness VS, Kennedy DN, Richelme C, Rademacher J, Filipek PA: The human brain ages 7 to 11 years: a volumetric analysis based on magnetic resonance images. Cereb Cortex 1996; 6:726-736","DOI":"10.1093\/cercor\/6.5.726"},{"key":"R1595BABJHAGJ","doi-asserted-by":"crossref","unstructured":"Henry ME, Moore CM, Kaufman MJ, Michelson D, Schmidt ME, Stoddard E, Vuckevic AJ, Berreira PJ, Cohen BM, Renshaw PF: Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. Am J Psychiatry 2000; 157:1506-1508","DOI":"10.1176\/appi.ajp.157.9.1506"},{"key":"R1595BABCEDHG","doi-asserted-by":"crossref","unstructured":"Bolo NR, Hode Y, Nedelec JF, Laine E, Wagner G, Macher JP: Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 2000; 23:428-438","DOI":"10.1016\/S0893-133X(00)00116-0"},{"key":"R1595BABIDCHA","doi-asserted-by":"crossref","unstructured":"Wilens TE, Biederman J, Baldessarini RJ, Puopolo PR, Flood JG: Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine. J Am Acad Child Adolesc Psychiatry 1992; 31:691-698","DOI":"10.1097\/00004583-199207000-00017"},{"key":"R1595BABCBCIB","doi-asserted-by":"crossref","unstructured":"Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA: Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci 1993; 5:322-329","DOI":"10.1176\/jnp.5.3.322"},{"key":"R1595BABDDEAE","doi-asserted-by":"crossref","unstructured":"Courchesne E, Karns CM, Davis HR, Ziccardi R, Carper RA, Tigue ZD, Chisum HJ, Moses P, Pierce K, Lord C, Lincoln AJ, Pizzo S, Schreibman L, Haas RH, Akshoomoff NA, Courchesne RY: Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. Neurology 2001; 57:245-254","DOI":"10.1212\/WNL.57.2.245"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.159.5.755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T14:13:53Z","timestamp":1722176033000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.159.5.755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,1]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5,1]]}},"alternative-id":["10.1176\/appi.ajp.159.5.755"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.159.5.755","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,1]]}}}